Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Chan Zuckerberg Biohub, San Francisco, CA 94158.
Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2317307121. doi: 10.1073/pnas.2317307121. Epub 2024 Apr 29.
Directing antibodies to a particular epitope among many possible on a target protein is a significant challenge. Here, we present a simple and general method for epitope-directed selection (EDS) using a differential phage selection strategy. This involves engineering the protein of interest (POI) with the epitope of interest (EOI) mutated using a systematic bioinformatics algorithm to guide the local design of an EOI decoy variant. Using several alternating rounds of negative selection with the EOI decoy variant followed by positive selection on the wild-type POI, we were able to identify highly specific and potent antibodies to five different EOI antigens that bind and functionally block known sites of proteolysis. Among these, we developed highly specific antibodies that target the proteolytic site on the CUB domain containing protein 1 (CDCP1) to prevent its proteolysis allowing us to study the cellular maturation of this event that triggers malignancy. We generated antibodies that recognize the junction between the pro- and catalytic domains for three different matrix metalloproteases (MMPs), MMP1, MMP3, and MMP9, that selectively block activation of each of these enzymes and impair cell migration. We targeted a proteolytic epitope on the cell surface receptor, EPH Receptor A2 (EphA2), that is known to transform it from a tumor suppressor to an oncoprotein. We believe that the EDS method greatly facilitates the generation of antibodies to specific EOIs on a wide range of proteins and enzymes for broad therapeutic and diagnostic applications.
将抗体引导至目标蛋白上的许多可能表位之一是一项重大挑战。在这里,我们提出了一种使用差异噬菌体选择策略的简单而通用的表位定向选择 (EDS) 方法。这涉及使用系统生物信息学算法对感兴趣的蛋白质 (POI) 进行工程改造,将感兴趣的表位 (EOI) 突变,以指导 EOI 诱饵变体的局部设计。使用 EOI 诱饵变体进行几轮负选择,然后对野生型 POI 进行正选择,我们能够鉴定出针对五个不同 EOI 抗原的高度特异性和有效的抗体,这些抗体能够结合并功能阻断已知的蛋白水解位点。在这些抗体中,我们开发了针对含 CUB 结构域蛋白 1 (CDCP1) 蛋白水解位点的高度特异性抗体,以阻止其蛋白水解,从而能够研究触发恶性肿瘤的这一事件的细胞成熟过程。我们生成了针对三种不同基质金属蛋白酶 (MMPs) MMP1、MMP3 和 MMP9 的前肽和催化结构域之间的连接的抗体,这些抗体选择性地阻断每种酶的激活并抑制细胞迁移。我们针对细胞表面受体 EPH 受体 A2 (EphA2) 的蛋白水解表位,该表位已知将其从肿瘤抑制因子转变为癌蛋白。我们相信,EDS 方法极大地促进了针对广泛的蛋白质和酶的特定 EOI 的抗体的产生,具有广泛的治疗和诊断应用。